Targeting CD40 in Waldenström's macroglobulinemia

Clinical Lymphoma and Myeloma

Volumn 9, Issue 1, 2009, Pages 87-89

  Lee, Mark ^a   Advani, Ranjana ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chronic lymphocytic leukemia; Multiple myeloma; Non Hodgkin lymphoma; Targeted agents; Waldenstr m

Indexed keywords

ANTINEOPLASTIC AGENT; CD40 ANTIGEN; CD40 LIGAND; HCD 122; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; SGN 40; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; B LYMPHOCYTE; BONE MARROW; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; HUMAN; IMMUNOGENICITY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PROTEIN TARGETING; WALDENSTROEM MACROGLOBULINEMIA; DRUG ANTAGONISM; IMMUNOLOGY; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; HUMANS; WALDENSTROM MACROGLOBULINEMIA;

EID: 67649547636     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.023     Document Type: Article

References (24)

1. Dimopoulos MA, Kyle RA, Anagnostopoulos A, et al. Diagnosis and Management of Waldenstrom's Macroglobulinemia. J Clin Oncol 2005; 23:1564-77.
2. Dimopoulos MA, Zervas C, Zornas A, et al. Treatment of Waldenstrom's Macroglobulinemia with rituximab. J Clin Oncol 2002; 20:2327-33.
3. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstrom's Macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007; 25:3344-9.
4. Treon SP, Hunter Z, Barnagan AR. CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia. Clin Lymphoma 2005; 5:273-7.
5. Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol 2000; 7(6 suppl 12):79-85.
6. Advani R, Forero-Torres A, Furman R et al. SGN-40 shows evidence of activity in patients with relapsed non-Hodgkin's lymphoma: Final results of a phase 1 doseescalation study. Annals Oncol 2008; 19(S4):99a.
7. Hussein MA, Berenson JR, Neisvizky R, et al. Results of a phase I trial of SGN-40 (anti-huCD40 mAb) in patients with relapsed multiple myeloma. Blood 2006; 108:1021a (Abstract 3576).
8. Byrd JC, Flinn IW, Khan KD, et al. Pharmacokinetics and pharmacodynamics from a first-in-human phase 1 dose escalation study with antagonist anti-CD40 antibody, HCD-122 (formerly CHIR-12.12) in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2006; 108:803a (Abstract 2837).
9. Bensinger W, Jagannath S, Becker PS, et al. A phase 1 dose escalation study of a fully human, antagonist anti-CD40 antibody, HCD122 (formerly CHIR-12.12) in patients with relapsed and refractory multiple myeloma. Blood 2006; 108:1021a (Abstract 3575).
10. Wang ES, Wetzler M. Targeting CD40. Leuk Lymphoma 2007; 48:229-31.
11. Younes A, Kadin ME: Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 2003; 21:3526-34.
12. Law CL, Gordon KA, Collier J, et al. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 2005; 65:8331-8.
13. Luqman M, Klabunde S, Lin K, et al. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 2008; 112:711-20.
14. Tai YT, Li X, Tong X, et al. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res 2005; 65:5898-06.
15. Gowda AC, Zhao XB, Cheney C, et al. Humanized anti CD-40 antibody SGN-40 effectively induces cytotoxicity against chronic lymphocytic leukemia (CLL) cells through antibody mediated cytotoxicity and demonstrates modest biologic evidence of CD40 activation. Blood 2005; 106:(Abstract 2966).
16. Campbell RA, Gordon MS, Sanchez E, et al. The humanized anti-CD40 antibody SGN-40 inhibits tumor growth in LAGk-1A, a CD40+ mouse model of human multiple myeloma. Blood 2006; 108:(Abstract 3506).
17. Long L, Patawaran M, Tong X, et al. Efficacy of an antagonistic anti-CD40 monoclonal antibody, HCD122 (CHIR-12.12), in preclinical models of human non-Hodgkin's lymphoma and Hodgkin's disease. Blood 2006; 108:320.
18. Schjetne KW, Fredriksen AB, Bogen B. Delivery of antigen to CD40 induces protective immune responses against tumors. J Immunol 2007; 178:4169-76.
19. Lewis TS, McCormick RS, Kissler K, et al. The humanized anti-CD40 monoclonal antibody, SGN-40, potentiates chemotherapy regimens in NHL xenograft models via pro-apoptotic signaling. Blood 2007; 110:692a (Abstract 2342).
20. Luqman M, Hsu SJ, Ericson M, et al: HCD122, an antagonist human anti-CD40 monoclonal antibody, enhances efficacy of CHOP in tumor xenograft model of human diffuse large B cell lymphoma. Blood 2007; 110:162a (Abstract 528).
21. Tournilhac O, Santos DD, Xu L, et al. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol 2006; 17:1275-82.
22. Ho AW, Hatjiharissi E, Ciccarelli BT, et al. CD27-CD70 interactions in the pathogenesis of Waldenstrom's Macroglobulinemia. Blood 2008; 112:4683-9.
23. Leleu X, Eeckhoute J, Jia X, et al. Targeting NF-B in Waldenstrom's Macroglobulinemia. Blood 2008; 111:5068-77.
24. Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's Macroglobulinemia: Results of WMCTG trial 03-248. Clin Can Res 2007; 13:3320-5.